WALTHAM, Mass.--Genome Therapeutics here has licensed its proprietary microbial sequence database, PathoGenome, to Hoechst Marion Roussel. The pharmaceutical company will use the database to develop antiinfective products. Hoechst will pay annual subscription fees and royalties for nonexclusive access to the database. PathoGenome contains genomic sequence information from 24 microbial organisms assembled through Genome Therapeutics' pathogen genomics research and public-domain sources, as well as in-depth sequence analysis and proprietary bioinformatics tools.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.